Impaired growth hormone response to human pancreatic growth hormone releasing factor [GRF (1-44)] in type 2 (non-insulin-dependent) diabetes

23Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Human pancreatic growth hormone releasing factor [GRF(1-44)] is the largest molecule of several peptides recently isolated from pancreatic tumours associated with acromegaly. It has been shown to stimulate the release of growth hormone in normal subjects and provides a safe and reliable tool for examining growth hormone release. A study was conducted to examine the release of growth hormone in patients with Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes. GRF(1-44) stimulated the release of growth hormone in normal subjects and produced no side effects. A response of similar magnitude occurred in Type 1 diabetic patients despite their concomitant hyperglycaemia. In contrast, the response in Type 2 diabetes was significantly impaired compared with normal volunteers (p<0.05) and Type 1 diabetic patients (p<0.02). These findings may well indicate that there is a defect in central hormonal control in Type 2 diabetes. © 1984 Springer-Verlag.

Cite

CITATION STYLE

APA

Richards, N. T., Wood, S. M., Christofides, N. D., Bhuttacharji, S. C., & Bloom, S. R. (1984). Impaired growth hormone response to human pancreatic growth hormone releasing factor [GRF (1-44)] in type 2 (non-insulin-dependent) diabetes. Diabetologia, 27(5), 529–534. https://doi.org/10.1007/BF00290390

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free